If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Please provide your email address to receive an email when new articles are posted on . The NIH has released new recommendations for the diagnosis, management and treatment of asthma in adolescents ...

Please provide your email address to receive an email when new articles are posted on . A previously proposed algorithm uses noninvasive and accessible biomarkers to classify patients with severe ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

Asthma is one of the most common long-term health conditions, so why does getting diagnosed and treated still rely on where you live, who you visit, or even your ethnicity? To commemorate World Asthma ...

As evidenced by a debate at the CHEST Annual Meeting 2023, the pulmonology community disagrees on whether the overlap of asthma and chronic obstructive pulmonary disease (COPD) is a distinct entity ...